How much should the resting heart rate be controlled in patients with atrial fibrillation and coronary heart disease? Authors: Yan-bo Wang, Qing-hua Yuan, Jie Yuan, Zhi-Min Du, Xiao-dong Zhuang, Xin-xue Liao Published: 2024 ABSTRACT BackgroundCurrent guidelines recommend maintaining a resting heart rate below 100–110 beats per minute (bpm) for patients with atrial fibrillation (AF). However, there is a lack of research on various treatment approaches for patients with both atrial fibrillation and coronary heart disease (AF&CHD). We have discussed the primary therapeutic options for controlling resting heart rate in patients with AF&CHD.MethodsWe conducted a post hoc analysis of the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial. Our study included 3986(98.2%) participants with AF, of which 1522 had AF&CHD. The primary outcome was all-cause mortality. We utilized the chi-squared test to identify significant differences in categorical variables. Multivariate Cox regression analysis was performed to compare the risk of death by standard deviation of heart rate visit to visit variability quartile.ResultsCompared to the AF group, a higher proportion of patients in the AF&CHD group had histories of smoking, hypertension, diabetes, heart failure, cardiomyopathy, valvular heart disease, peripheral vascular disease, bradycardia, hepatic or renal disease, pulmonary disease, and stroke (all P < 0.001). Additionally, patients with AF&CHD were more likely to undergo coronary artery bypass grafting (CABG) and pacemaker surgeries than those with AF alone. After adjusting for multiple clinical variables, patients with AF&CHD had a significantly higher risk of all-cause mortality compared to the AF group (RR = 1.79, 95% CI: 1.49–2.60; P < 0.01). Nonlinear multivariate curve-fitting analysis identified an optimal resting heart rate of 70 bpm for patients with AF&CHD (P < 0.001). Subgroup analysis revealed that patients with a resting heart rate below 70 bpm had lower all-cause mortality than those with a resting heart rate above 70 bpm (P < 0.001).ConclusionsFor resting heart rates below 70 bpm, our results suggest an inverse causal relationship between genetically determined resting heart rate and all-cause mortality in patients with AF&CHD.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-024-04349-1. Introduction Atrial fibrillation (AF) is the most common sustained arrhythmia, with its incidence and prevalence rising worldwide [1]. Over the past 50 years, AF incidence has increased four to fivefold [2], and its prevalence is projected to double between 2010 and 2030 [3]. The lifetime risk of AF is approximately 30–40% among White individuals, about 20% among African American individuals [4], and around 15% among Chinese individuals [5]. AF is linked to increased healthcare utilization and costs [6]. Although the number of deaths from coronary heart disease (CHD) has declined over the past decade, CHD remains the leading cause of death globally, creating a significant burden on individuals and societies [7]. AF and CHD share many epidemiological and pathophysiological characteristics, with studies indicating that patients with CHD have an increased likelihood of developing AF [8, 9]. The incidence of AF following acute coronary syndrome (ACS) ranges from 10 to 21%, with the risk increasing with patient age and the severity of myocardial infarction (MI) [8, 9]. Coronary artery disease severity, age, and left ventricular ejection fraction (LVEF) may contribute to an increased risk of new-onset atrial fibrillation in MI patients [10]. Atrial fibrillation is an independent predictor of poor long-term outcomes in ACS patients [11]. The Framingham Study [12] showed that CHD doubled the risk of various forms of AF in men and quadrupled the risk of transient AF in women. Additionally, AF independently raises the likelihood of new coronary events by 2.2 times [13]. Another study demonstrated that CHD is an independent risk factor for stroke in patients with AF [14]. CHD and AF intensify each other’s effects, potentially creating a vicious cycle. Resting heart rate (RHR) serves as a crucial indicator of autonomic nervous system function. Elevated heart rate (HR) increases myocardial oxygen demand, contributes to fatigue, and can damage the elastic fibers of arterial walls, potentially accelerating the progression of atherosclerosis. RHR is recognized as an independent risk factor for both all-cause mortality and cardiovascular mortality in individuals with coronary atherosclerosis [15]. Currently, there is a consensus that reducing heart rate can help lower mortality rates in patients with coronary artery disease [16]. Epidemiological studies have linked higher RHR with a greater risk of MI, AF, stroke, and all-cause mortality [17], although the evidence remains somewhat inconsistent. Previous studies have investigated the association between RHR and the incidence of AF. Some findings suggest that a low RHR may increase the risk of developing AF [18–21], while others indicate that both high and low RHR are linked to AF, implying a U-shaped relationship [22–24]. A meta-analysis found a significant J-shaped association between RHR and AF, with higher RHR linked to an elevated risk of AF compared to a moderate RHR range of 68–80 bpm [24]. In recent years, guidelines for resting heart rate control in patients with AF have been updated based on new research evidence. According to the 2016 ESC Guidelines, a target heart rate of 60–110 bpm is recommended for AF patients with acute or chronic heart failure [25]. The 2023 ACC/AHA/ACCP/HRS Guidelines generally suggest maintaining a resting heart rate below 100–110 bpm for AF patients [26], based on evidence from the RACE II trial, which found that lenient rate control (< 110 bpm) was as effective as strict rate control (< 80 bpm) in patients with persistent AF [27]. For patients with CHD and heart failure (HF), guidelines recommend maintaining a resting heart rate between 55 and 60 bpm [28]. There are currently no clear guidelines regarding resting heart rate control for patients with AF&CHD, and large-scale studies in this population are lacking. It remains uncertain whether interventions to lower resting heart rates are beneficial in patients with coexisting AF&CHD. This study aims to determine the optimal level of resting heart rate control in this specific patient group. Methods Database access The current analysis is based on the randomized Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial conducted by the US National Heart, Lung, and Blood Institute [29, 30]. The AFFIRM study was approved by the AFFIRM Steering Committee, the Institutional Review Board of the University of Washington (Clinical Trial Center), and the Institutional Review Boards of each participating site [30]. In the AFFIRM trial, 4,060 patients (mean age: 70 years; age range: 49–80 years) with paroxysmal or persistent atrial fibrillation were randomized to receive either rate-control or rhythm-control strategies [30]. These patients had AF along with at least one additional risk factor for stroke or death (age ≥ 65 years, hypertension, diabetes, or congestive heart failure). The mean follow-up duration was 3.5 years. All participants provided written informed consent. The study adhered to the European Union Note for Guidance on Good Clinical Practice (CPMP/ECH/135/95) and the Declaration of Helsinki. Based on the inclusion and exclusion criteria, a total of 3,986 patients were included in this analysis. Patients were classified based on the presence or absence of a history of CHD, as defined by the investigators. At the time of randomization, detailed information on the history of significant CHD, associated risk factors, and medications was collected through a structured questionnaire based on the 1997 AFFIRM study design [30]. After randomization, patients underwent regular follow-up, and all-cause mortality was documented. Quality of heart rate control The quality of RHR control was assessed using RHR and electrocardiogram heart rate data collected from follow-up forms completed by physicians during scheduled visits at 2, 4, 8, and 12 months, and then every 4 months thereafter. As per the study design, all investigators documented the occurrence of major adverse events at the site level using the follow-up forms, providing comprehensive clinical details. HR analysis was conducted for patients who met the following criteria: (1) at least one year of HR observations; (2) a minimum of four HR measurements available. The standard deviation (SD) of the mean HR during follow-up was calculated for each patient. The SD of heart rate (HR-SD) was used to assess visit-to-visit heart rate variability (VVHRV), and patients were categorized into quartiles (1st, 2nd, 3rd, and 4th) based on their HR-SD. Following the study protocol, all investigators recorded all-cause mortality as a key clinical outcome using the follow-up forms. Statistical analysis All statistical analyses were conducted using SPSS version 24.0; the R statistical software package (http://www.R-project.org), R Foundation; and Fengrui statistical software version 1.9.2. Categorical variables were analyzed using the chi-squared test, with a two-sided P-value of less than 0.05 considered statistically significant. Continuous variables were presented as mean and SD or median and interquartile range (IQR), depending on their distribution. For continuous variables, the t-test was used for normally distributed data, while the Mann-Whitney U test was applied for non-normally distributed data. Initially, we compared baseline characteristics and all-cause mortality between two groups: AF patients with and without CHD. The distribution of resting heart rates in both groups was described. To further investigate the relationship between various covariates (including age, gender, smoking status, hypertension, diabetes, stroke, heart failure, and peripheral vascular disease) and clinical outcomes, we employed multivariate binary logistic regression. Cox regression analysis was performed to assess whether HR-SD quartiles, treated as a continuous variable, were independently associated with an increased risk of adverse clinical outcomes. Kaplan-Meier curves were generated based on HR-SD quartiles to illustrate clinical outcomes. The model was adjusted for all covariates using multivariate logistic regression to determine the optimal resting heart rate range in AF patients with CHD. Results Baseline characteristics of the participants We analyzed data from the AFFIRM trial, including 3,986 participants (98.2% of the total cohort) for the current analysis. Participants were divided into two groups: the AF & CHD group (n = 1,522, 38.2%) and the AF group (n = 2,464, 61.8%), based on the presence or absence of coronary heart disease. Baseline demographic and clinical characteristics for the two groups are presented in Table 1. The mean age did not differ significantly between the two groups: 70.3 ± 9.2 years in the AF & CHD group versus 70.9 ± 9.3 years in the AF group (P = 0.059). Patients in the AF & CHD group had a significantly higher prevalence of smoking habit, hypertension, diabetes, heart failure, cardiomyopathy, valvular heart disease, peripheral vascular disease, bradycardia, hepatic or renal disease, pulmonary disease, and stroke (all P < 0.001). Additionally, a greater proportion of patients in the AF & CHD group required coronary artery bypass grafting (CABG) and pacemaker implantation compared to the AF-only group, with statistical significance (P < 0.001). The AF & CHD group also exhibited a higher overall mortality rate (P < 0.001). Table 1Basic characteristics of atrial fibrillation with coronary heart disease or notVariablesTotal (n = 3986)0 (n = 2464)1 (n = 1522) p Age, mean ± SD70.6 ± 9.270.9 ± 9.370.3 ± 9.20.059Male sex, n (%)1563(39.2)1108(45.0)455(30.0)< 0.001SBP, mmHg, Mean ± SD135.4 ± 14.4136.1 ± 13.9134.3 ± 15.0< 0.001Hypertension, n (%)< 0.001 01156(29.0)766(31.1)390(25.6) 12830(71.0)1698(68.9)1132(74.4)Heart Failure, n (%)< 0.001 03073(77.1)2079(84.4)994(65.3) 1913(22.9)385(15.6)528(34.7)Cardiomyopathy, n (%)< 0.001 03658 (91.8)2304 (93.5)1354 (89) 1328 (8.2)160 (6.5)168 (11)Valvular heart disease, n (%)< 0.001 03496 (87.7)2204 (89.4)1292 (84.9) 1490 (12.3)260 (10.6)230 (15.1)Congenital heart disease, n (%)0.174 03965 (99.5)2448 (99.4)1517 (99.7) 121 (0.5)16 (0.6)5 (0.3)Bradycardia, n (%)< 0.001 03708 (93.0)2344 (95.1)1364 (89.6) 1278 (7.0)120 (4.9)158 (10.4)Stroke, n (%)< 0.001 03459 (86.8)2176 (88.3)1283 (84.3) 1527 (13.2)288 (11.7)239 (15.7)Peripheral vascular disease, n (%)< 0.001 03716 (93.2)2361 (95.8)1355 (89) 1270 (6.8)103 (4.2)167 (11)Diabetes mellitus, n (%)< 0.001 03188 (80.0)2069 (84)1119 (73.5) 1798 (20.0)395 (16)403 (26.5)Hepatic/renal disease, n (%)< 0.001 03767 (94.5)2352 (95.5)1415 (93) 1219 (5.5)112 (4.5)107 (7)Pulmonary disease, n (%)< 0.001 03406 (85.4)2169 (88)1237 (81.3) 1580 (14.6)295 (12)285 (18.7)Smoker, n (%)0.038 03501 (87.8)2185 (88.7)1316 (86.5) 1485 (12.2)279 (11.3)206 (13.5)CABG, n (%)< 0.001 03485 (87.4)2464 (100)1021 (67.1) 1501 (12.6)0 (0)501 (32.9)Pacemaker, n (%)< 0.001 03741 (93.9)2349 (95.3)1392 (91.5) 1245 (6.1)115 (4.7)130 (8.5)Died, n (%)< 0.001 03365(84.4)2190(88.9)1175(75.4) 1621(15.6)274(11.1)347(24.6) Table 1Basic characteristics of atrial fibrillation with coronary heart disease or notVariablesTotal (n = 3986)0 (n = 2464)1 (n = 1522) p Age, mean ± SD70.6 ± 9.270.9 ± 9.370.3 ± 9.20.059Male sex, n (%)1563(39.2)1108(45.0)455(30.0)< 0.001SBP, mmHg, Mean ± SD135.4 ± 14.4136.1 ± 13.9134.3 ± 15.0< 0.001Hypertension, n (%)< 0.001 01156(29.0)766(31.1)390(25.6) 12830(71.0)1698(68.9)1132(74.4)Heart Failure, n (%)< 0.001 03073(77.1)2079(84.4)994(65.3) 1913(22.9)385(15.6)528(34.7)Cardiomyopathy, n (%)< 0.001 03658 (91.8)2304 (93.5)1354 (89) 1328 (8.2)160 (6.5)168 (11)Valvular heart disease, n (%)< 0.001 03496 (87.7)2204 (89.4)1292 (84.9) 1490 (12.3)260 (10.6)230 (15.1)Congenital heart disease, n (%)0.174 03965 (99.5)2448 (99.4)1517 (99.7) 121 (0.5)16 (0.6)5 (0.3)Bradycardia, n (%)< 0.001 03708 (93.0)2344 (95.1)1364 (89.6) 1278 (7.0)120 (4.9)158 (10.4)Stroke, n (%)< 0.001 03459 (86.8)2176 (88.3)1283 (84.3) 1527 (13.2)288 (11.7)239 (15.7)Peripheral vascular disease, n (%)< 0.001 03716 (93.2)2361 (95.8)1355 (89) 1270 (6.8)103 (4.2)167 (11)Diabetes mellitus, n (%)< 0.001 03188 (80.0)2069 (84)1119 (73.5) 1798 (20.0)395 (16)403 (26.5)Hepatic/renal disease, n (%)< 0.001 03767 (94.5)2352 (95.5)1415 (93) 1219 (5.5)112 (4.5)107 (7)Pulmonary disease, n (%)< 0.001 03406 (85.4)2169 (88)1237 (81.3) 1580 (14.6)295 (12)285 (18.7)Smoker, n (%)0.038 03501 (87.8)2185 (88.7)1316 (86.5) 1485 (12.2)279 (11.3)206 (13.5)CABG, n (%)< 0.001 03485 (87.4)2464 (100)1021 (67.1) 1501 (12.6)0 (0)501 (32.9)Pacemaker, n (%)< 0.001 03741 (93.9)2349 (95.3)1392 (91.5) 1245 (6.1)115 (4.7)130 (8.5)Died, n (%)< 0.001 03365(84.4)2190(88.9)1175(75.4) 1621(15.6)274(11.1)347(24.6) Basic characteristics of atrial fibrillation with coronary heart disease or not Multivariable analysis In the logistic regression analysis for the risk of AF&CHD (Table 2), there was no statistically significant difference observed in VVHRV (P ≥ 0.05) when compared to atrial fibrillation. Using the 1st quartile as a reference, the hazard ratios for the 2nd, 3rd, and 4th quartiles were 1.11 (95% CI: 0.86–1.43, P = 0.43), 1.18 (95% CI: 0.91–1.53, P = 0.22), and 1.19 (95% CI: 0.92–1.55, P = 0.18), respectively, all of which were not statistically significant (P ≥ 0.05). The multivariable analysis (Table 2) indicated that factors such as age, sex, body mass index(BMI), standard deviation of systolic blood pressure (SBP), hypertension, diabetes mellitus, myocardial infarction, and heart failure were associated with an increased risk of AF&CHD (P < 0.05). Table 2Association of covariates and AF&CHD riskRR95%CI P HR-SD--0.53 HR-SD (1)1.11(0.86–1.43)0.43 HR-SD (2)1.18(0.91–1.53)0.22 HR-SD (3)1.19(0.92–1.55)0.18SBP-SD1.03(1.01–1.05)< 0.01SBP-MEAN0.99(0.98–0.99)< 0.01BMI1.01(0.99–1.02)< 0.01Age1.04(1.02–1.05)< 0.01Heart Failure2.44(1.96–3.04)< 0.01Hypertension1.26(1.02–1.57)0.03Stroke1.19(0.91–1.55)0.21Peripheral vascular disease2.08(1.43–3.02)< 0.01Diabetes1.56(1.25–1.96)< 0.01Smoker1.03(0.77–1.36)0.87Rhythm1.12(0.93–1.34)0.23Gender0.41(0.34–0.50)< 0.01Died1.79(1.49–2.60)< 0.01 Table 2Association of covariates and AF&CHD riskRR95%CI P HR-SD--0.53 HR-SD (1)1.11(0.86–1.43)0.43 HR-SD (2)1.18(0.91–1.53)0.22 HR-SD (3)1.19(0.92–1.55)0.18SBP-SD1.03(1.01–1.05)< 0.01SBP-MEAN0.99(0.98–0.99)< 0.01BMI1.01(0.99–1.02)< 0.01Age1.04(1.02–1.05)< 0.01Heart Failure2.44(1.96–3.04)< 0.01Hypertension1.26(1.02–1.57)0.03Stroke1.19(0.91–1.55)0.21Peripheral vascular disease2.08(1.43–3.02)< 0.01Diabetes1.56(1.25–1.96)< 0.01Smoker1.03(0.77–1.36)0.87Rhythm1.12(0.93–1.34)0.23Gender0.41(0.34–0.50)< 0.01Died1.79(1.49–2.60)< 0.01 Association of covariates and AF&CHD risk Survival analysis During a mean follow-up of 3.5 years, 621 patients (15.6%) died from all causes. Specifically, there were 347 deaths (8.7%) in the AF&CHD group and 274 deaths (6.9%) in the AF group (P < 0.01, shown in Tables 1 and 2). Figure 1 illustrates that the all-cause mortality was significantly higher in the AF&CHD group compared to the AF group during the follow-up period (P < 0.001) across the entire cohort. Furthermore, when stratified by the quartiles of HR-SD, the study found that lower quartiles of HR-SD were associated with a higher risk of total mortality (P < 0.001). Extended follow-up showed that individuals in the highest HR-SD quartile had a greater risk of all-cause mortality compared to those in the lowest quartile. The relationship between VVHRV and adverse outcomes in all patients exhibited a U-shaped curve. Figure 2 shows that among patients with AF&CHD, those with an RHR below 70 bpm had significantly lower all-cause mortality compared to those with an RHR above 70 bpm (P < 0.0001). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of resting heart rate for mortality in patients with AF&CHD. The analysis yielded an AUC 95% CI: 60.383% (57.0596% ~ 63.7064%), as shown in Supplementary Material 1. Fig. 1Kaplan–Meier curves survival analysis of heart rate in all patients Kaplan–Meier curves survival analysis of heart rate in all patients Fig. 2Kaplan–Meier survival analysis of heart rate in Atrial fibrillation with coronary heart disease Kaplan–Meier survival analysis of heart rate in Atrial fibrillation with coronary heart disease Threshold effect analysis and sensitive analysis Figure 3 illustrates the difference in heart rates between the AF&CHD group and the AF group. The mean heart rate in the AF&CHD group was significantly higher than in the AF group (70.7 bpm vs. 70 bpm, P = 0.048). Figure 4 demonstrates that after adjusting for age, gender, smoking status, BMI, standard deviation of SBP, mean SBP, hypertension, diabetes mellitus, myocardial infarction, and heart failure, the relationship between heart rate and long-term mortality in patients with AF&CHD exhibited a nonlinear pattern. A threshold effect was observed, where a resting heart rate > 70 bpm was significantly associated with increased all-cause mortality (P < 0.001). Fig. 3Distribution of heart rate in patients with AF group by status of coronary heart disease Distribution of heart rate in patients with AF group by status of coronary heart disease Fig. 4The nonlinear relationship between mean heart rate and long-time mortality in Atrial fibrillation with coronary heart disease. Adjusted for all covariates as models The nonlinear relationship between mean heart rate and long-time mortality in Atrial fibrillation with coronary heart disease. Adjusted for all covariates as models Discussion Based on the post hoc subgroup analysis of atrial fibrillation (AF) cohorts over a 3.5-year period using data from the AFFIRM study, we found that visit-to-visit heart rate variability (VVHRV) in patients with AF and coronary heart disease (CHD) was associated with all-cause mortality and clinical events. After adjusting for factors such as age, gender, smoking status, body mass index (BMI), the standard deviation of systolic blood pressure (SBP), the mean of SBP, the presence of hypertension, diabetes mellitus, myocardial infarction, and heart failure (HF), the analysis suggested that maintaining a resting heart rate below 70 beats per minute (bpm) in patients with AF and CHD may be associated with better outcomes. Numerous studies have demonstrated that both low and high resting heart rates (RHR) are associated with an increased risk of developing AF [19, 20, 23, 24]. The Kailuan prospective cohort study [23] revealed a U-shaped relationship between RHR and the incidence of AF in the general Chinese population. It is now widely accepted that RHR correlates with AF episodes, while surface electrocardiography may also serve as a predictive tool for such episodes. In a study [31] involving patients with cardiac implantable electronic devices (CIEDs), prolonged of P wave peak time in V1 lead (PWPTV1) was identified as a potential risk factor for atrial high-rate episodes (AHRE), which were significantly associated with the incidence of clinical AF. Meanwhile, heart rate control has become an integral part of the treatment for atrial fibrillation. However, existing studies on the impact of heart rate (HR) on the prognosis of patients with AF are inconsistent. Some studies have shown that RHR has no effect on outcomes in AF [32], while lenient rate control has been found to be as effective as strict rate control in patients with permanent AF [27, 33]. Another study found a J-shaped relationship between heart rate and mortality in patients with permanent AF [34]. Meanwhile, current studies on the effects of heart rate control in patients with AF and heart failure also show inconsistencies. In patients with AF and heart failure, controlling the heart rate to below 70 beats/min was not associated with improved survival [35], whereas a heart rate exceeding 100 beats/min was linked to increased mortality [36]. There is still controversy regarding the target heart rate for patients with atrial fibrillation combined with other heart diseases. Over the past few decades, CHD has been the leading cause of death in both developed and developing countries. Research has indicated that patients with CHD are more likely to develop AF [12]. It has also been reported that patients with AF are more likely to have coronary artery lesions [13]. CHD and AF can mutually exacerbate each other, forming a vicious cycle. Patients with CHD and AF tend to have worse outcomes, with higher complication and mortality rates [12]. For these patients, existing primary studies and guidelines have focused on antithrombotic treatment and rhythm control, with a lack of studies on heart rate control. Our study focuses on the goal of controlling resting heart rate in patients with AF combined with CHD. It is now generally accepted that the resting heart rate for permanent AF is controlled below 100–110 bpm, but there is no clear target for resting heart rate control in patients with AF&CHD. Our study attempted to find the optimal resting heart rate control in patients with AF&CHD. After adjusting for other risk factors, we found a threshold effect in the cohort of patients with AF&CHD when the resting heart rate was below 70 bpm. A lower RHR was associated with a decreased survival time in patients with AF&CHD. Subsequent subgroup survival analysis indicated that patients with an RHR below 70 bpm had a higher survival rate compared to those with an RHR above 70 bpm. This suggests that maintaining an RHR around 70 bpm may be beneficial for these patients, as both excessively high and low RHR may adversely affect survival outcomes. At the same time, we compared the survival difference between the AF group and the AF&CHD group. The results showed that in the AF&CHD group, there was a higher mortality rate, a higher proportion of pacemaker implantation, and a higher proportion of coronary artery bypass grafting, with statistical significance, which is consistent with existing studies. Moreover, we analyzed the impact of heart rate variability (HRV) on prognosis in patients with AF during follow-up visits. A multi-center study in Thailand revealed a J-curve effect of HRV on all-cause mortality in patients with AF [37]. This finding is similar to our study, which identified a U-shaped relationship between VVHRV and all-cause mortality. Another study, using data from the Kailuan study cohort, indicated that both higher and lower VVHRV might increase the risk of new-onset AF [38]. These findings imply that VVHRV could potentially serve as a predictor of all-cause mortality in patients with AF, regardless of the presence of CHD. However, further research is needed to confirm this. Conclusions In AF patients with CHD, controlling resting heart rates below 70 bpm may inversely affect the causal association with all-cause mortality. There are implications from this data that effective rate control could be a potential therapeutic goal for AF&CHD, and this opens new avenues for future study. These findings are speculative observations, and well-designed prospective clinical studies are required to confirm these preliminary findings. Limitations There are several limitations in our study. Firstly, this study constitutes a retrospective analysis of the AFFIRM trial. Randomization was restricted to the entire treatment strategy population, not the subgroups extracted for this report, thus rendering effective covariate control unfeasible. Secondly, the visit-to-visit heart rate, instead of the long-term heart rate, was selected as the resting heart rate, potentially resulting in less comprehensive outcomes. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3